CytRx (CYTR) Completes Aldoxorubicin Phase 2b Enrollment in SCLC
Tweet Send to a Friend
CytRx Corporation (Nasdaq: CYTR) announced that it has reached its enrollment target of 132 patients for the company's global Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
